Combined oral contraceptives: Venous thrombosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  de Bastos, Marcos ^a   Stegeman, Bernardine H ^b   Rosendaal, Frits R ^c   Van Hylckama Vlieg, Astrid ^c   Helmerhorst, Frans M ^c   Stijnen, Theo ^c   Dekkers, Olaf M ^c  

^a Instituto Previdencia dos Servidores do Estado de Minas Gerais   (Brazil)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DROSPIRENONE; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; ANDROSTANE DERIVATIVE; CYPROTERONE; PREGNANE DERIVATIVE;

DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG SAFETY; HUMAN; INCIDENCE; LUNG EMBOLISM; META ANALYSIS; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; VEIN THROMBOSIS; CHEMICALLY INDUCED DISORDER; FEMALE;

ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; CYPROTERONE; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; NORPREGNENES; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOSIS;

EID: 84903489282     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010813.pub2     Document Type: Review

References (154)

1. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sorensen HT, Baech J, Gregersen H. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998;79:28-31.
2. Bird ST, Delaney JA, Etminan M, Brophy JM, Hartzema AG. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?. J Thromb Haemost. 2013;11:1059-68.
3. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
4. Bloemenkamp KW, Rosendaal FR, Buller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159:65-70.
5. Farmer R. Safety of modern oral contraceptives. Lancet 1996;347:259.
6. Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study. Contraception 1998;57:67-70.
7. Farmer RD, Lawrenson RA, Todd JC, Williams TJ, MacRae KD, Tyrer F, Leydon GM. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000;49:580-90.
8. Gronich 2011. Gronich N, Lavi I, Rennert G [Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study]. CMAJ 2011;183:E1319-25.
9. Hedenmalm K, Samuelsson E, Spigset O. Pulmonary embolism associated with combined oral contraceptives: reporting incidences and potential risk factors for a fatal outcome. Acta Obstet Gynecol Scand 2004;83:576-85.
10. Heinemann LA, Lewis MA, Assmann A, Thiel C. A methodological study on venous thromboembolism and steroid hormone use. Contraception 2002;65:207-14.
11. Heinemann LA, Dinger JC, Assmann A, Minh TD. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation 'pill scare'. Contraception 2010;81:401-7.
12. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999;354:127-8.
13. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006;73:566-70.
14. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
15. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996;54:5-13.
16. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96.
17. Lidegaard O, Nielsen H, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
18. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999;19:700-3.
19. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4.
20. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.
21. Samuelsson E, Hagg S. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstet Gynecol Scand 2004;83:674-81.
22. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database. Hum Reprod 1999;14:1500-5.
23. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
24. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contarception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. The Lancet 1995;346:1575-82.
25. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-8.
26. Amundsen T, Hoibraaten E, Skjeldestad FE. [Pulmonary embolism among young non-pregnant women]. Tidsskr. Nor Laegeforen 2000;120:326-9.
27. Austin H, Lally C, Benson JM, et al.Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. Am J Obstet Gynecol 2009;200:620. e1-620.e3.
28. Barsoum MK, Heit JA, Ashrani AA, Leibson CL, Petterson TM, Bailey KR. A population-based case-control study. Thrombosis Research 2010;126:373-8.
29. Boston Collaborative Drug Surveillance Programme. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours. Lancet 1973;7817:1399-1404.
30. Bergendal A, Bremme K, Hedenmalm K, Larfars G, Odeberg J, Persson I, et al.Risk factors for venous thromboembolism in pre- and postmenopausal women. Thrombosis Research 2012;130:596-601.
31. Bernstein D, Coupey S, Schonberg K. Pulmonary Embolism in Adolescents. AJDC 1986;140:667-671.
32. Bonifacj C, Quere I, Dupuy C, Janbon C, Daures JP. Case control studies of the risk factors for deep-vein thrombosis in an adult population hospitalized in internal medicine. Rev Epidemiol Sante Publique 1997;45:465-73.
33. Bottiger LE. Oral contraceptives and Thromboembolic disease: effects of lowering oestrogen contente. The Lancet 1980;8178:1097-1101.
34. Burnhill MS, The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives. Int J Fertil. Womens Med 1999;44:19-30.
35. Diddle AW, Gardner WMH, Williamson PH, Johnson JR, Hemphill JL, Godwin CW. Oral contraceptives steroids and thrombophlebitis. J Tenn Med Assoc 1978;71:22-26.
36. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on oral contraceptives based on 142, 475 women-years of observation. Contraception 2007;75:344-354.
37. Dinger J, Assmann A, Mohner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:123-9.
38. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf 2008;17:297-305.
39. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG. Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
40. Fuertes A, Curet JO, Pelegrina I, Bangdiwala I. Thrombophlebitis among oral contraceptives for contraception. Obstet Gynecol 1971;38:259-263.
41. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
42. Girolami A, Spiezia L, Girolami B, Zocca N, Luzzatto G. Effect of Age on Oral Contraceptive-Induced Venous Thrombosis. Clin Appl Thromb Hemost 2004;10:259-263.
43. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7.
44. Grounds M. Anovulants: thrombosis and other associated changes. Med J Aust 1974;2:440-6.
45. Hall K, Trussell J. Types of Combined Oral Contraceptives Used by Us Women, Including Women at Risk of Venous Thromboembolism. Contraception 2012;86:313-4.
46. Hedenmalm K, Samuelsson E. Fatal venous thromboembolism associated with different combined oral contraceptives. A study of incidences and potential biases in spontaneous reporting. Drug Safety 2005;28:907-916.
47. Heinemann LA, Garbe E, Farmer R, Lewis MA. Venous thromboembolism and oral contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J Contracept Reprod Health Care 2000;5:183-191.
48. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91-5.
49. Herings RM, Urquhart J, Leufkens HG. Venous thromboembolism and oral contraceptives. Lancet 1999;354:127-8.
50. Heuser P, Tonga K, Hopkins R, Henderson M, Weatherall M, Metcalfe S, Beasley R. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission. N Z M J 2004;117:U1176.
51. Hirvonen E. Cardiovascular death among women under 40 years of age using low-estrogen oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol 1990;163:281-4.
52. Huerta C, Johansson S, Wallander M, Rodriíguez LAG. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-943.
53. Inman WH, Chir B, Vessey MP. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. BMJ 1968;2:193-9.
54. Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs. British Medical Journal 1970;2:203-209.
55. Anonymous, Prospective long-term study of women on different contraceptives. IPPF. Med Bull 1976;10:2-3.
56. Kieler H, Persson I, Odlind V. Thromboembolism and combined oral contraceptives. Spontaneous reporting of adverse drug reactions indicate at least similar risk with themost recent contraceptives. Läkartidningen 2003;100:3050-2.
57. Lambrekht R, Vageman V, Vinkelman B, Geinrikh P. [Hormonal contraceptive agents as a risk factor in the development of acute thromboembolic diseases]. Khirurgiia (Mosk) 1986;12:90-3.
58. Lawrenson R, Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference?. Contraception 2000;62:21S-28S.
59. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, Coccheri S. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002;23:984-90.
60. Lewis MA, Spitzer WO. The role of bias in observational studies. Contraception 1997;55:189-194.
61. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Human Reproduction 1999;14:1493-9.
62. Lewis MA, MacRae KD, Kuhl-Habich D, Heinemann LA. Venous thromboembolism and oral contraceptives. Lancet 1999;354:1470.
63. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism. A case-control study. Contraception 1998;57:291-301.
64. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998;179:S62-S67.
65. Lidegaard O, Schiodt AV, Poulsen EF. Oral contraceptives and thrombosis. Ugeskr Laeger 2001;163 (34):4549-4553.
66. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.
67. Lindqvist PG, Epstein E, Olsson H. The relationship between lifestyle factors and venous thromboembolism among women: a report from the MISS study. British Journal of Haematology 2009;144:234-240.
68. Lis Y, Spitzer WO, Mann RD, Cockburn I, Chukwujindu J, Thorogood M, et al.A concurrent cohort study of oral contraceptive use and cardiovascular risks. Pharmacoepidemiol Drug Saf 1993;2:51-63.
69. Ludwig H. Ovulationshemmer und Venenerkrankungen. Ergebnisse der Angiologie und Phlebologie 1970;4:81-102.
70. Martinelli I, Battaglioli T, Mannucci PM. Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. Pharmacogenetics 2003;13:589-594.
71. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-mcg oestrogen preparations. BMJ 1980;280:1157-61.
72. Meinel H, Göretzlehner G, Heinemann L. Hormonal contraceptives and cardiovascular risk. Results of an East German multicenter case control study]. Zentralbl Gynakol 1988;110:1507-14.
73. Meurer LN, Slawson JG. What is the risk of venous thromboembolism (VT) among women taking third generation oral contraceptives ((COCs) in comparison with those taking contraceptives containing levonorgestrel?. The Journal of Family Practice 2001;50:108.
74. Nightingale L, Lawrenson RA, Simpson EL, Williams TJ, MacRae KD, Farmer RD. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5:265-274.
75. Overgaard K, Hauch O, Lidegaard O. [Venous thromboembolic disease and oral contraceptives]. Ugeskr Laeger 1986;148:2348-2350.
76. Pearce HM, Layton D, Wilton LV, Shakir SAW. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. British Journal of Clinical Pharmacology 2005;60:98-102.
77. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979;242:1150-4.
78. Pini M, Scoditti U, Caliumi F, Manotti C, Quintaballa R, Pattacini A, Poli T, Tagliaferri A, di Lasio MG, Bernardi F. Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias. Recenti Prog Med 1996;87:331-7.
79. Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease - recent experience. Obstet Gynecol 1982;59:299-302.
80. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4.
81. Poulter NR, Farley TM, Chang CL, Marmot MG, Meirik O. Safety of combined oral contraceptive pills (letter). Lancet 1996;347:547.
82. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005;41:603-8.
83. Quinn DA, Thompson BT, Terrin ML, Thrall JH, Athanasoulis CA, McKusick KA, Stein PD, Hales CA. A Prospective investigation of pulmonary embolism in women and men. JAMA 1992;268:1689-1696.
84. Royal College of General Practitioners' oral contraception study. Oral contraceptives, venous thrombosis, and varicose veins. Journal ofthe Royal College of General Practitioners 1978;28:393-9.
85. Realini JP, Encarnacion CE, Chintapalli KN, Rees CR. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias. J Am Board Fam Pract 1997;10:315-321.
86. Reed S, Bardenheuer K, Dinger J. . 2012, Conference: . VTE risk in users of combined oral contraceptives: Impact of a 24-day regimen containing drospirenone. Pharmacoepidemiology and Drug Safety 2012;Conference:169-170.
87. Roach REJ, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. Journal of Thrombosis and Haemostasis 2013;11:124-131.
88. Seaman HE, de Vries CS, Farmer RDT. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette1): observational studies using the UK General Practice Research Database. Pharmacoepidemiology and Drug Safety 2004;13:427-436.
89. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110(3):587-93.
90. Seigel DG, Markush RE. Oral contraceptives and relative risk of death from venous and pulmonary thromboembolism in the United States. American Journal of Epidemiology 1969;90(1):11-16.
91. Sidney S, Petitti DB, Soff DG, Cundiff DL, Tolan KK, Quesenberry Jr. CP. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004;70:3-10.
92. Spitzer WO, Thorogood M, Heinemann L. Trinational case control study of OCs and health. Pharmacoepidemiol Drug Saf 1993;2:21-31.
93. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975;102:197-208.
94. Suissa S, Blais L, Spitzer WO, Cusson SJ, Lewis JM, Heinemanns L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997;56:141-6.
95. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venousthromboembolism in young women: A case-control study. International Journal of Epidemiology 1992;.21(1):48-52.
96. Tosetto A, Frezzato M, Rodeghiero F. Prevalence and risk factors of venoud non-fatal venous thromboembolism in the active population of the VITA project. J Thromb Haermost 2003;1:1724-9.
97. Tzankova V, Petrov V, Danchev N. Impact of oral contraceptives and smoking on arterial and deep venous thrombosis: A retrospective case-control study. Biotechnology & Biotechnological Equipment 2010;24:2026-30.
98. Tsankova V, Petrov V, Astrug A. [Oral contraceptives increase deep venous thrombosis in smoking women], Akush . Ginekol. 2010 (Sofiia);49(5):8-13.
99. Ulmer H, Pfeifer C, Pfeiffer KR, Bruppacher R. Hospitalization of young women after selected cardiovascular and thromboembolic incidents in Austria 1993 and 1994 [Hospitalisierung von jungen Frauen nach ausgew ihlten kardiovaskul iren und thromboembolischen Ereignissen in Osterreich 1993 und 1994]. Soz-Praventivmed 1997;42:342-350.
100. Vallee JP. [Risk of venous thromboembolism among users of third-generation oral contraceptives]. Presse Med 2001 Mar 24;30:535-6.
101. Van der Meer FJM, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thrombosis and Haemostasis 1997;78:631-5.
102. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives andthromboembolic disease. A further report. BMJ 1969;2(5658):651-7.
103. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986;292:526.
104. WHO Collaborative Study. Cardiovascular disease and use of oral contraceptives. Bulletin of the World Health Organization 1989;67:417-423.
105. Worralurt C, Taneepanichskul S. Risk factors of venous thromboembolism (VT) in Thai reproductive aged female: King Chulalongkorn Memorial Hospital experience. J Med Assoc Thai 2005;88:1502-5.
106. Yang CC, Kao CC. Cardiovascular diseases and the risk of venous thromboembolism: A hospital-based case-control study. J Chin Med Assoc 2007;70:103-9.
107. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Thrombophilias and gynaecology. Best Practice & Research. Clinical Obstetrics & Gynaecology 2003;17(3):509-28.
108. Castoldi E, Rosing J. APC resistance: biological basis and acquired influences. Journal of Thrombosis and Haemostasis 2010;8:445-53.
109. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al.Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):1-173.
110. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [PUBMED: 9310563]
111. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD003989.pub5]
112. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Medicine 2011;8:e1001026.
113. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormonal replacement therapy: a clinical review. Archives of Internal Medicine 2004;164:1965-76.
114. Goodacre S, Sampson F, Stevenson M, Wailoo A, Sutton A, Thomas S, et al.Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technology Assessment 2006;10(15):1-168.
115. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36.
116. Henzl MR, Edwards JA. Pharmacology of progestins: 17 alpha-hydroxyprogesterone derivatives and progestins of the first and second generation. Progestins and antiprogestins in clinical practice. Marcel Dekker, Inc, New York, USA, 2000:101-32.
117. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
118. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value in Health 2008;11:956-64.
119. Jordan W. Pulmonary embolism. Lancet 1961;278:1146-7.
120. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30.
121. Kemmeren JM, Algra A, Grobbee DF. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001;323:1-9.
122. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation. Blood Coagulation & Fibrinolysis 2002;13:373-81.
123. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thrombosis and Haemostasis 2002;87:199-205.
124. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et al.Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-33.
125. Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008;77:77-83.
126. Kristman VL, Manno M, Côté P. Methods to account for attrition in longitudinal data: do they work?. European Journal of Epidemiology 2005;20:657-62.
127. Kuhl H. Dienogest. Drugs 1998;56:834-5.
128. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venousthromboembolism: a systematic review and meta-analysis.. Drug Saf 2012;35:191-205.
129. Næss IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis 2007;5:692-9.
130. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al.The Joint American Academy of Family Physicians/American College of Physicians Panel on deep venous thrombosis/pulmonary embolism. Practice guideline from the American Academy of Family Physicians and the American College of Physicians. Annals of Family Medicine 2007;5:57-62.
131. Rad M, Kluft C, Menard J, Burggraaf J, de Kam ML, Meijer P, et al.Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinylestradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. American Journal of Obstetrics and Gynecology 2006;195:72-7.
132. Sanderson S, Tatt ID, Higgins JPT. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. International Journal of Epidemiology 2007;36:666-76.
133. Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Updates 2006;12:169-78.
134. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61(1-2):151-7.
135. StataCorp LP. STATA Data analysis and statistical software. StataCorp LP, 2011.
136. Tans G, Van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, et al.Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. British Journal of Haematology 2003;122:465-70.
137. Thijs V, Lemmens R, Fieuws S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. European Heart Journal 2008;29:1086-92.
138. Thorogood M, Villard-Mackintosh L. Combined oral contraceptives: risks and benefits. British Medical Bulletin 1993;49:124-39.
139. Tick LW, Doggen CJ, Rosendaal FR, Faber WR, Bousema MT, Mackay AJ, et al.Predictors of the post-thrombotic syndrome with non-invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis. Journal of Thrombosis and Haemostasis 2010;8:2685-92.
140. van Hylckama Vlieg, A, Helmerhorst FM, Rosendaal FR. The risk of deep venousthrombosis associated with injectable depot-medroxyprogesterone acetate contraceptivesor a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010;30:2297-300.
141. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now?. Journal of Thrombosis and Haemostasis 2011;9:257-66.
142. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
143. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. American Journal of Obstetrics and Gynecology 1997;177:887-91.
144. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al.Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine 2001;344:1527-35.
145. Vandenbroucke JP. Benefits and harms of drug treatments. BMJ 2004;329:2-3.
146. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment?. Canadian Medical Association Journal 2006;174:645-6.
147. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Medicine 2008;5:339-43.
148. Wells PS, Hirsh J, Anderson DR, Lensing AW, Foster G, Kearon C, et al.Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995;345:1326-30.
149. Wharton C, Blackburn R. Lower dose pills. Population Reports 1988;16:1-31.
150. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-8.
151. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in networkmeta-analysis: model estimation using multivariate meta-regression. Research Synthesis Methods 2012;3:111-25.
152. Anonymous . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.
153. Anonymous . Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organization Technical Report Series 1998;877:1-89.
154. Stegeman BH, de Bastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, et al.Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:f5298. [PUBMED: 24030561]